Skip to Content

Mayo Clinic Laboratory and Pathology Research Roundup: March 12

By Kelley Luedke • March 12, 2018

The Research Roundup provides an overview of the past week’s research from Mayo Medical Laboratories consultants, including featured abstracts and complete list of published studies and reviews.

Featured Abstract

Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers

BRCA1 and BRCA2 mutation carriers can be at increased cardiovascular risk. Mayo Clinic researchers conducted a review to provide information about factors associated with increased cardiovascular risk, methods to prevent cardiovascular toxicities, and recommended screening guidelines. BRCA1/2 mutation carriers who are diagnosed with cancer are often exposed to chemotherapy, chest radiotherapy, and/or HER2 directed therapies, all of which can be cardiotoxic. In addition, BRCA1/2 carriers often undergo prophylactic salpingoopherectomies, which may also increase cardiovascular risks. Understanding the potential for increased cardiovascular risk in individuals with a BRCA1 or BRCA2 mutation, as well as gold standard practices for prevention, detection, and treatment of cardiac concerns in this population, is important. The study was published in Current Treatment Options in Cardiovascular Medicine.

Published to PubMed This Week

Kelley Luedke

Kelley Luedke

Kelley Luedke is a Marketing Channel Manager at Mayo Clinic Laboratories. She is the principle editor and writer of Insights and leads social media and direct marketing strategy. Kelley has worked at Mayo Clinic since 2013. Outside of work, you can find Kelley running, traveling, playing with her kitty, and exploring new foods.

Related Posts
Mayo Clinic Laboratory and Pathology Research Roundup: September 14
Mayo Clinic Research Advances Diagnostics to Lead COVID-19 Pandemic Response
Mayo Clinic’s Accurate Amyloidosis Typing Test Leads to Effective Treatment